Pacific Shuanglin Bio-pharmacy Hits Day Low at CNY 10.60 Amid Price Pressure

Pacific Shuanglin Bio-pharmacy Co., Ltd. has experienced a significant decline today, with the stock dropping by 5.01% and reaching an intraday low of CNY 10.60. This performance stands in stark contrast to the China Shanghai Composite, which has only decreased by 0.43% on the same day. Over the past week, Pacific Shuanglin has seen a more pronounced decline of 7.21%, while its monthly performance remains slightly positive at 0.46%. However, the longer-term outlook reveals a troubling trend, with the stock down 41.06% over the past year and a staggering 67.19% over the last five years. The company's financial metrics indicate ongoing challenges, including a notable drop in net sales by 8.47% and negative results reported for the last six consecutive quarters. Additionally, the operating cash flow has reached a low of CNY -201.95 million, and the return on capital employed stands at just 4.38%. These figures highlight the difficulties faced by Pacific Shuanglin in maintaining its market position within the pharmaceuticals and biotechnology sector.